Press Release: June 12, 2020
BIOTECHNOLOGY company Novavax rolled out its first human trials for its coronavirus vaccine on Tuesday. Novavax already tested its vaccine on animals in low doses and found it successful. The Maryland-based company will inject 131 volunteers in the Australian cities of Melbourne and Brisbane, with results of the clinical trial expected to be made public in July.
Phase 1 of the trial is a "randomised, observer-blinded, placebo-controlled trial" that assesses two different dosage sizes of the vaccine among healthy participants age 18 to 59. Novavax is one of several pharmaceutical companies racing to develop coronavirus vaccines, with Pfizer and Moderna launching human trials earlier this month.
About Novavax - Creating Tomorrow´s Vaccines Today
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. More at: https://novavax.com